Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Dubin

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Journal of Virology|June 17, 1998
In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptorT Nagashunmugam, J Lubinski, L Wang, et al.
Journal of Virology|June 17, 1998
Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complexT Peng, M Ponce de Leon, M J Novotny, et al.
Lancet (London, England)|July 10, 2009
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenJ Paavonen, P Naud, J Salmerón, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 28, 2026
Multidisciplinary Consensus Statement for Appropriate Evaluation and Workup of Sinonasal MassesNyall R London, Jerlon Chiu, Neal S Akhave, et al.
Vaccine|July 16, 2013
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial, R R Abu-Elyazeed, T Heineman, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Journal of Virology|June 17, 1998
In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptorT Nagashunmugam, J Lubinski, L Wang, et al.
Journal of Virology|June 17, 1998
Structural and antigenic analysis of a truncated form of the herpes simplex virus glycoprotein gH-gL complexT Peng, M Ponce de Leon, M J Novotny, et al.
Lancet (London, England)|July 10, 2009
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenJ Paavonen, P Naud, J Salmerón, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 28, 2026
Multidisciplinary Consensus Statement for Appropriate Evaluation and Workup of Sinonasal MassesNyall R London, Jerlon Chiu, Neal S Akhave, et al.
Vaccine|July 16, 2013
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial, R R Abu-Elyazeed, T Heineman, et al.
International Journal of Cancer|August 23, 2011
Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18A Szarewski, W A J Poppe, S R Skinner, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 6